## Bradley C Martin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1630026/publications.pdf

Version: 2024-02-01

74 papers

6,569 citations

35 h-index 91712 69 g-index

74 all docs

74 docs citations

74 times ranked 7872 citing authors

#	Article	IF	Citations
1	Association between discontinuing chronic opioid therapy and newly diagnosed substance use disorders, accidents, selfâ€inflicted injuries and drug overdoses within the prescribers' health care system: a retrospective cohort study. Addiction, 2022, 117, 946-968.	1.7	4
2	Impact of transitioning from long-term to intermittent opioid therapy on the development of opioid-related adverse outcomes: A retrospective cohort study. Drug and Alcohol Dependence, 2022, 231, 109236.	1.6	1
3	Using data science to improve outcomes for persons with opioid use disorder. Substance Abuse, 2022, 43, 956-963.	1.1	4
4	Associations Between Early Chiropractic Care and Physical Therapy on Subsequent Opioid Use Among Persons With Low Back Pain in Arkansas. Journal of Chiropractic Medicine, 2022, 21, 67-76.	0.3	5
5	Statewide trends and factors associated with genetic testing for hereditary cancer risk in Arkansas 2013–2018. Hereditary Cancer in Clinical Practice, 2022, 20, .	0.6	O
6	Perceptions of HPV vaccination and pharmacist-physician collaboration models to improve HPV vaccination rates. Exploratory Research in Clinical and Social Pharmacy, 2021, 2, 100014.	0.6	2
7	Characteristics and Network Influence of Providers Involved in the Treatment of Patients With Chronic Back, Neck or Joint Pain in Arkansas. Journal of Pain, 2021, 22, 1681-1695.	0.7	O
8	Trajectories of Opioid Coverage After Long-Term Opioid Therapy Initiation Among a National Cohort of US Veterans. Journal of Pain Research, 2021, Volume 14, 1745-1762.	0.8	8
9	Opioid overdose counseling and prescribing of naloxone in rural community pharmacies: A pilot study. Exploratory Research in Clinical and Social Pharmacy, 2021, 2, 100019.	0.6	6
10	Association Between Pain Intensity and Discontinuing Opioid Therapy or Transitioning to Intermittent Opioid Therapy After Initial Long-Term Opioid Therapy: A Retrospective Cohort Study. Journal of Pain, 2021, 22, 1709-1721.	0.7	3
11	Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users. Value in Health, 2020, 23, 451-460.	0.1	18
12	Impact of opioid dose escalation on the development of substance use disorders, accidents, selfâ€inflicted injuries, opioid overdoses and alcohol and nonâ€opioid drugâ€related overdoses: a retrospective cohort study. Addiction, 2020, 115, 1098-1112.	1.7	35
13	Impact of opioid dose escalation on pain intensity: a retrospective cohort study. Pain, 2020, 161, 979-988.	2.0	17
14	Communication between pharmacists and primary care physicians in the midst of a U.S. opioid crisis. Research in Social and Administrative Pharmacy, 2019, 15, 974-985.	1.5	14
15	Impact of Medical Marijuana Legalization on Opioid Use, Chronic Opioid Use, and High-risk Opioid Use. Journal of General Internal Medicine, 2019, 34, 1419-1426.	1.3	46
16	Claims for contraceptive services among young women filling chronic opioid prescriptions. Contraception, 2019, 99, 296-299.	0.8	2
17	Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study. Research in Social and Administrative Pharmacy, 2019, 15, 754-760.	1.5	40
18	Sleep deficiency among Native Hawaiian/Pacific Islander, Black, and White Americans and the association with cardiometabolic diseases: analysis of the National Health Interview Survey Data. Sleep Health, 2018, 4, 273-283.	1.3	26

#	Article	IF	CITATIONS
19	Lack of Impact of the 2009 USPSTF Guidelines on Rates of Mammography Screening. Journal of Women's Health, 2018, 27, 875-884.	1.5	5
20	Prevalence of Chronic Kidney Disease, Thrombotic Cardiovascular Events, and Use of Oral P2Y12 Inhibitors among Veterans. American Journal of Nephrology, 2018, 47, 67-71.	1.4	6
21	Relationship between concomitant benzodiazepine-opioid use and adverse outcomes among US veterans. Pain, 2018, 159, 451-459.	2.0	95
22	Factors Associated with Opioid Initiation in OEF/OIF/OND Veterans with Traumatic Brain Injury. Pain Medicine, 2018, 19, 774-787.	0.9	19
23	APPE Evaluations are Positively Associated with MMI, Pre-pharmacy GPA and Pharmacy GPA. American Journal of Pharmaceutical Education, 2018, 82, 6326.	0.7	13
24	Comparison of Low-, Moderate-, and High-Molecular-Weight Hyaluronic Acid Injections in Delaying Time to Knee Surgery. Journal of Arthroplasty, 2017, 32, 2952-2957.e21.	1.5	25
25	Pharmacoepidemiologic analyses of opioid use among OEF/OIF/OND veterans. Pain, 2017, 158, 1039-1045.	2.0	40
26	Comparative Effectiveness of Intra-Articular Hyaluronic Acid and Corticosteroid Injections on the Time to Surgical Knee Procedures. Journal of Arthroplasty, 2017, 32, 3591-3597.e24.	1.5	19
27	Factors Influencing Long-Term Opioid Use Among Opioid Naive Patients: An Examination of Initial Prescription Characteristics and Pain Etiologies. Journal of Pain, 2017, 18, 1374-1383.	0.7	204
28	Costâ€Effectiveness of Histamine <sub>2</sub> Receptor Antagonists Versus Proton Pump Inhibitors for Stress Ulcer Prophylaxis in Critically III Patients. Pharmacotherapy, 2017, 37, 43-53.	1.2	23
29	Progression to Uncontrolled Severe Asthma: A Novel Risk Equation. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 44-50.	0.5	1
30	Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use — United States, 2006–2015. Morbidity and Mortality Weekly Report, 2017, 66, 265-269.	9.0	751
31	Assessing the Medication Adherence App Marketplace From the Health Professional and Consumer Vantage Points. JMIR MHealth and UHealth, 2017, 5, e45.	1.8	42
32	Multiple Mini-Interview Performance Predicts Academic Difficulty in the PharmD Curriculum. American Journal of Pharmaceutical Education, 2016, 80, 27.	0.7	25
33	Assessment of medication adherence app features, functionality, and health literacy level and the creation of a searchable Web-based adherence app resource for health care professionals and patients. Journal of the American Pharmacists Association: JAPhA, 2016, 56, 293-302.	0.7	40
34	Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. Stroke, 2016, 47, 1555-1561.	1.0	53
35	Predictive Validity of the Beers and Screening Tool of Older Persons' Potentially Inappropriate Prescriptions (STOPP) Criteria to Detect Adverse Drug Events, Hospitalizations, and Emergency Department Visits in the United States. Journal of the American Geriatrics Society, 2016, 64, 22-30.	1.3	77
36	Author response to "Impact of survival bias on opioid-related outcomes when using death as an exclusion criterion― Pharmacoepidemiology and Drug Safety, 2016, 25, 477-478.	0.9	0

#	Article	IF	Citations
37	The influence of propoxyphene withdrawal on opioid use in veterans. Pharmacoepidemiology and Drug Safety, 2015, 24, 1180-1188.	0.9	14
38	Exploring the possible association between montelukast and neuropsychiatric events among children with asthma: a matched nested caseâ€control study. Pharmacoepidemiology and Drug Safety, 2015, 24, 435-445.	0.9	30
39	Net Clinical Benefits of Guidelines and Decision Tool Recommendations for Oral Anticoagulant Use among Patients with Atrial Fibrillation. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 2845-2853.	0.7	6
40	National study of discontinuation of long-term opioid therapy among veterans. Pain, 2014, 155, 2673-2679.	2.0	57
41	The Role of Opioid Prescription in Incident Opioid Abuse and Dependence Among Individuals With Chronic Noncancer Pain. Clinical Journal of Pain, 2014, 30, 557-564.	0.8	424
42	Patterns of opioid use for chronic noncancer pain in the Veterans Health Administration from 2009 to 2011. Pain, 2014, 155, 2337-2343.	2.0	85
43	A Questionnaire to Assess the Relevance and Credibility of Observational Studies to Inform Health Care Decision Making:ÂAn ISPOR-AMCP-NPC Good Practice Task Force Report. Value in Health, 2014, 17, 143-156.	0.1	96
44	Smartphone medication adherence apps: Potential benefits to patients and providers. Journal of the American Pharmacists Association: JAPhA, 2013, 53, 172-181.	0.7	365
45	The Costs of Warfarin Underuse and Nonadherence in Patients with Atrial Fibrillation: A Commercial Insurer Perspective. Journal of Managed Care Pharmacy, 2013, 19, 302-316.	2.2	87
46	Prescription-Acquired Acetaminophen Use and the Risk of Asthma in Adults: A Case-Control Study. Annals of Pharmacotherapy, 2012, 46, 1598-1608.	0.9	13
47	Mental Health Disorders and Long-term Opioid Use Among Adolescents and Young Adults With Chronic Pain. Journal of Adolescent Health, 2012, 50, 553-558.	1.2	59
48	Anticoagulation Therapy for Patients with Non-Valvular Atrial Fibrillation. American Journal of Cardiovascular Drugs, 2012, 12, 313-323.	1.0	24
49	Acute and Chronic Acetaminophen Use and Renal Disease: A Case-Control Study Using Pharmacy and Medical Claims. Journal of Managed Care Pharmacy, 2012, 18, 234-246.	2.2	19
50	Prescription-acquired acetaminophen use and potential overuse patterns: 2001-2008. Pharmacoepidemiology and Drug Safety, 2012, 21, 226-230.	0.9	10
51	Increasing Time Costs and Copayments for Prescription Drugs: An Analysis of Policy Changes in a Complex Environment. Health Services Research, 2011, 46, 900-919.	1.0	33
52	Long-Term Chronic Opioid Therapy Discontinuation Rates from the TROUP Study. Journal of General Internal Medicine, 2011, 26, 1450-1457.	1.3	182
53	Trends in Use of Opioids for Chronic Noncancer Pain Among Individuals With Mental Health and Substance Use Disorders: The TROUP Study. Clinical Journal of Pain, 2010, 26, 1-8.	0.8	227
54	An Analysis of Heavy Utilizers of Opioids for Chronic Noncancer Pain in the TROUP Study. Journal of Pain and Symptom Management, 2010, 40, 279-289.	0.6	84

#	Article	IF	CITATIONS
55	Risks for possible and probable opioid misuse among recipients of chronic opioid therapy in commercial and medicaid insurance plans: The TROUP Study. Pain, 2010, 150, 332-339.	2.0	245
56	Risks for opioid abuse and dependence among recipients of chronic opioid therapy: Results from the TROUP Study. Drug and Alcohol Dependence, 2010, 112, 90-98.	1.6	271
57	Prospective Validation of Eight Different Adherence Measures for Use with Administrative Claims Data among Patients with Schizophrenia. Value in Health, 2009, 12, 989-995.	0.1	109
58	Good Research Practices for Comparative Effectiveness Research: Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Reportâ€"Part II. Value in Health, 2009, 12,	0.1	246
59	1053-1061. Good Research Practices for Comparative Effectiveness Research: Analytic Methods to Improve Causal Inference from Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part III. Value in Health. 2009. 12. 1062-1073.	0.1	234
60	Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Current Medical Research and Opinion, 2009, 25, 2303-2310.	0.9	464
61	Contrasting Measures of Adherence with Simple Drug Use, Medication Switching, and Therapeutic Duplication. Annals of Pharmacotherapy, 2009, 43, 36-44.	0.9	191
62	The Impact of Overweight and Obesity on the Direct Medical Costs of Truck Drivers. Journal of Occupational and Environmental Medicine, 2009, 51, 180-184.	0.9	46
63	Trends in use of opioids for non-cancer pain conditions 2000–2005 in Commercial and Medicaid insurance plans: The TROUP study. Pain, 2008, 138, 440-449.	2.0	323
64	Trends in Use of Opioids by Noncancer Pain Type 2000-2005 Among Arkansas Medicaid and HealthCore Enrollees: Results From the TROUP Study. Journal of Pain, 2008, 9, 1026-1035.	0.7	83
65	An Empirical Basis for Standardizing Adherence Measures Derived From Administrative Claims Data Among Diabetic Patients. Medical Care, 2008, 46, 1125-1133.	1.1	157
66	The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia. Current Medical Research and Opinion, 2007, 23, 1351-1365.	0.9	14
67	The initial development of the WebMedQual scale: Domain assessment of the construct of quality of health web sites. International Journal of Medical Informatics, 2006, 75, 42-57.	1.6	64
68	Direct medical costs of constipation in the United States. Managed Care Interface, 2006, 19, 43-9.	0.2	54
69	An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population. Pharmacoepidemiology and Drug Safety, 2005, 14, 629-638.	0.9	49
70	Prevalence, Trends, and Factors Associated With Antipsychotic Polypharmacy Among Medicaid-Eligible Schizophrenia Patients, 1998–2000. Journal of Clinical Psychiatry, 2004, 65, 1377-1388.	1.1	193
71	A Checklist for Retrospective Database Studies—Report of the ISPOR Task Force on Retrospective Databases. Value in Health, 2003, 6, 90-97.	0.1	328
72	Formulary Management of Low Molecular Weight Heparins. Pharmacoeconomics, 2000, 17, 1-12.	1.7	11

#	Article	IF	CITATIONS
73	Evaluation of six computerized drug interaction screening programs. American Journal of Health-System Pharmacy, 1992, 49, 1430-1435.	0.5	1
74	Association between Opioid Therapy Trajectories and Potential Opioidâ€Related Adverse Health Events. Pharmacoepidemiology and Drug Safety, 0, , .	0.9	2